GlassScriptPhysician profile
Suhas R Patel
NPI 1104844778
$3,279.81
in general payments reported to CMS, 2019-2025
28 companies · $393 in 2025
The $393 reported for 2025 was more than what 75% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
See the full distribution for Geriatric Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $370 · 2020: $236 · 2021: $567 · 2022: $545 · 2023: $531 · 2024: $638 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,561.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $525.60 | 2019-2025 | Kisunla, Amyvid, Jardiance |
| Abbvie INC. | $447.37 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $318.07 | 2023-2025 | Rexulti, Nuedexta |
| Astrazeneca Pharmaceuticals LP | $316.14 | 2020-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $263.71 | 2019-2025 | |
| Astellas Pharma US INC | $260.75 | 2019-2023 | Veozah |
| Novartis Pharmaceuticals Corporation | $207.42 | 2019-2023 | |
| Exact Sciences Corporation | $138.21 | 2024-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $127.38 | 2019-2022 | |
| Eisai INC. | $84.06 | 2021-2025 | |
| Boston Scientific Corporation | $64.41 | 2019 | |
| Nestle Healthcare Nutrition INC. | $57.78 | 2020-2023 | |
| Sunovion Pharmaceuticals INC. | $50.63 | 2019 | |
| Novo Nordisk INC | $49.61 | 2022-2025 | Rybelsus, Ozempic |
| Lundbeck LLC | $47.10 | 2024-2025 | Rexulti |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $41.16 | 2020-2022 | |
| Acadia Pharmaceuticals INC | $40.37 | 2022-2023 | Nuplazid |
| Aimmune Therapeutics, INC. | $32.16 | 2024 | |
| Corium, LLC | $29.38 | 2023 | Adlarity |
| Xeris Pharmaceuticals, INC. | $28.59 | 2022-2023 | Gvoke Hypopen |
| Avanir Pharmaceuticals, INC. | $27.79 | 2019-2022 | |
| Amarin Pharma, INC. | $27.77 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $18.22 | 2024 | Austedo Xr |
| Topcon Healthcare Solutions, INC. | $17.31 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $17.21 | 2021 | |
| Neurocrine Biosciences, INC. | $14.69 | 2022 | |
| Abbott Laboratories | $14.11 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suhas Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.